{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4IrvhYUJDA","lastupdate":"2021-10-31T00:00:00.000Z","update_date":"2021-10-31T00:00:00.000Z","lastModified":"Aug 14, 2025","active":1,"confidence_score":91,"confidence_score_reason":"markets, not claimed","urlname":"immunai","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$GH8p88MaCJb7c2NVf1vof017FyaDsnVb831iA8QvgkNVu2yfTkaAuK","name":"Immunai","oneliner":"Peripheral Tissue Analysis","registrar":"515981934","website":"https://www.immunai.com","careerspage":"https://www.immunai.com/careers","founded_month":1,"founded_year":2019,"formernames":[],"sociallinks":{"twitter":"https://twitter.com/Immunaitech","youtube":"https://www.youtube.com/channel/UChTYZlcgoung0EZlsgq-G6g","facebook":"","linkedin":"https://www.linkedin.com/company/53085519","instagram":""},"social":["https://twitter.com/Immunaitech","https://www.youtube.com/channel/UChTYZlcgoung0EZlsgq-G6g","https://www.linkedin.com/company/53085519"],"flattenedsociallinks":"https://twitter.com/Immunaitech|https://www.youtube.com/channel/UChTYZlcgoung0EZlsgq-G6g|https://www.linkedin.com/company/53085519","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"51-200","employees_exact":192,"patent":0,"raised":295000000,"stage":"B","public_stage":"B","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["AIMUNA MEDICAL","Immune.ai","AMICA","Immun.ai","aimuna","Immun-ai","Immune-ai","Immun AI"],"about":"Immunai is developing a proprietary data set of multi-omic, immune-centric peripheral tissue analyses. The company's advanced analytics and data-visualization interface allows researchers to comprehensively view and interrogate data and to derive novel conclusions on the underlying mechanisms of disease.\n\nThe platform is currently being used to develop and refine cell therapies for neuroblastoma in conjunction with the Baylor College of Medicine.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"","country":null,"address":{"israeli":[{"id":"ae5d754b-50bf-4927-a07c-ce9693df086a","city":"Tel Aviv-Yafo","type":null,"address":"Tel Aviv, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":[{"id":"599d1522-193d-4ae9-946a-f241c587cd04","city":"New York","address":"430 E 29th St, New York, NY, USA","country":"United States","placeid":null}]},"headquarter_address":null,"district":"Center District","news":[{"id":"iFutZPgclCCsLd9SPERo68BU2RCghy0YsVwTjwfu9CFLcet19IYhwX","date":"Oct 16, 2025","link":"https://www.calcalistech.com/ctechnews/article/hj8zlcr6ex","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"partnership","round":null,"company":"Immunai","layoffs":null,"summary":"Immunai, an Israeli AI biotech company, has entered into a new agreement with AstraZeneca to develop a novel therapeutic target for inflammatory bowel disease (IBD). This partnership leverages Immunais Immunodynamics Engine (IDE) and its proprietary immune cell atlas, AMICA, which integrates single-cell multi-omics data with machine learning. AstraZeneca will have exclusive rights to develop and commercialize therapeutics aimed at the newly identified target, with Immunai receiving an upfront payment and potential earnings of up to $85 million based on development milestones. This agreement marks a significant milestone in Immunais ongoing collaboration with AstraZeneca, which began in 2022 and included an $18 million investment in 2024 to enhance oncology clinical trials.","partners":"AstraZeneca","customers":null,"eventType":null,"investors":"AstraZeneca","confidence":9,"key_topics":["AI","partnership","IBD","therapeutics","immune system"],"date_of_event":"2024","product_stage":"released","investment_date":"2024","acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"18 million","structured_issues":["Partners","Investment"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"dgjBtexv47WN3r2tvLriIJ8w414VWhHySHqQr1ZjueJidxeoWAm3gI","news_summary":"AI biotech expands partnership after uncovering novel immune target with its machine learning platform.","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"MQYgpfC1advypZJEeHMhhdADfSKpLf5CUW0lwCGqWVjL3pYBhGTQ68","date":"Nov 14, 2024","link":"https://www.calcalistech.com/ctechnews/article/bkp9md7zjg","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"collaboration","company":"Immunai","layoffs":null,"summary":"Immunai, an AI biotech company specializing in mapping the human immune system, has announced a multi-year collaboration with Teva Pharmaceuticals. This partnership aims to enhance clinical decision-making in Tevas immunology trials using Immunais proprietary immune cell atlas and AI model. The collaboration will focus on drug mechanism of action, dose selection, and biomarker analyses. This reflects Immunais ongoing efforts to streamline drug development processes. The collaboration is expected to provide insights into patient responses and treatment mechanisms, optimizing clinical trials and improving patient outcomes. Immunai recently announced a similar collaboration with AstraZeneca, valued at $18 million. Immunai, which employs 170 people, raised a $215 million Series B at a valuation of just over $1 billion in 2021.","partners":["Teva Pharmaceuticals","AstraZeneca"],"customers":null,"investors":null,"confidence":9,"key_topics":["AI","Immunology","Collaboration","Drug Development","Clinical Trials"],"date_of_event":"Less than two months ago","valuation_amount":"$1 billion","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"x1znUiqxxL4FapYpCjvEA8ULcg4ghiS4M6wRhujDHKR1GYfBikmXf8","news_summary":"Immunai and Teva launch multi-tear AI collaboration for smarter drug development | CTech","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"eRl2j6biHB5y8sYxcLfWwPOXBEFgqAiD2I1I8TAcnCJ02epCINChFS","date":"Nov 14, 2024","link":"https://www.calcalistech.com/ctechnews/article/bkp9md7zjg","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"collaboration","company":"Immunai","layoffs":null,"summary":"Immunai, an AI biotech company specializing in mapping the human immune system, has entered a multi-year collaboration with Teva Pharmaceuticals. This partnership aims to enhance Tevas Immunology and Immuno-oncology programs by leveraging Immunais immune cell atlas and AI model to improve clinical decision-making. The collaboration will focus on drug mechanism of action, dose selection, and biomarker analyses. This partnership reflects Immunais ongoing efforts to streamline drug development and deliver new therapies to patients. Additionally, Immunai recently announced a collaboration with AstraZeneca, valued at $18 million, to enhance cancer drug trials. Immunai has raised a total of $295 million, including a $215 million Series B round in 2021, with a valuation of just over $1 billion.","partners":["Teva Pharmaceuticals","AstraZeneca"],"customers":[],"investors":[],"confidence":9,"key_topics":["AI","Immunology","Collaboration","Drug Development","Clinical Trials"],"date_of_event":"Not explicitly mentioned","valuation_amount":"just over $1 billion","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"MtCeqIS4Q7EA0dfDO10BT0ziN2ecXUmf68KeAhCWlcwCwBE9swxRTk","news_summary":"The partnership will utilize Immunai’s cutting-edge immune system mapping tools to enhance precision in immunology and oncology trials.  ","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"xWuIoCRlxfWsNfECJyvQ5BDeZ2mBxBeegqPrvF1MQngCyYCrVSO4op","date":"Sep 26, 2024","link":"https://www.calcalistech.com/ctechnews/article/syx7my7a0","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"collaboration","company":"Immunai","layoffs":null,"summary":"Israeli biotech startup Immunai has announced a multi-year collaboration with AstraZeneca, focusing on clinical decision-making and leveraging Immunais AI model of the immune system. Immunai will receive $18 million for the initial phase, with AstraZeneca having the option to extend the collaboration. The partnership aims to improve clinical trial success rates and R&D productivity. Immunai, which employs 170 people, raised a $215 million Series B at a valuation of just over $1 billion in 2021. This collaboration is part of AstraZenecas broader strategy to use AI in drug discovery and development.","partners":["AstraZeneca"],"customers":null,"investors":"AstraZeneca","confidence":10,"key_topics":["collaboration","AI","immune system","clinical trials","biomarkers"],"date_of_event":"2023-10","valuation_amount":"$1 billion","impact_on_company":"growth-positive","investment_amount":"$18 million","structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Kc2UN7i4b5fCzi4krujQ3mrwA9nSKjeSuWB6u1FFyyP5VDBJp53brP","news_summary":"The collaboration will focus on clinical decision-making, including dose selection, elucidating mechanisms of action, patient responder vs. non-responder analysis, and biomarker identification, by leveraging the Israeli biotech unicorn’s AI model of the immune system. ","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"DZ7J6uyPxkHH8aCM0Fuih9ZMcYoIm73WCBbNF3IwGav5f8QqZ21cdo","date":"Sep 26, 2024","link":"https://en.globes.co.il/en/article-israels-immunai-expands-strategic-1001490529","source":"en.globes.co.il","visible":1,"analysis":{"tags":"partnership","company":"Immunai","layoffs":"0","summary":"Israeli company Immunai, which develops AI-based tools for drug discovery, has entered into a strategic agreement with AstraZeneca. The deal is initially worth $18 million, but its significance lies in the planned multi-year collaboration between the two companies. Immunais platform, which models the human immune system, aims to improve the efficiency of drug development. The company has raised $300 million to date, including $215 million in a single round in 2021, and currently employs 170 people. AstraZenecas chief data scientist highlighted the potential of Immunais platform to enhance their R&D strategy.","partners":["AstraZeneca"],"customers":[],"investors":["AstraZeneca"],"confidence":10,"key_topics":["AI","drug development","partnership","investment","pharmaceuticals"],"date_of_event":"September 26, 2024","valuation_amount":"$1 billion","impact_on_company":"growth-positive","investment_amount":"$18 million","structured_issues":["Partners","Investment"],"acquisition_amount":"0","structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"bN0VHNsUVZh2yK48w6Stnf0qxcMeNlegpkTyooaLtkcFrDM6Qw2UL3","news_summary":"The agreement is worth an initial $18 million to Immunai, developer of an AI-based model for making drug development more efficient.","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"50dc2401-3ebd-492b-b71d-dc37d9eacad4","date":"Oct 27, 2021","link":"https://techcrunch.com/2021/10/27/immunai-announces-a-215m-series-b-as-its-immune-cell-atlas-matures/","source":"techcrunch.com","visible":1,"analysis":{"tags":"biotech, funding, data, machine learning, drug development","company":"Immunai","layoffs":null,"summary":"Biotech startup Immunai has raised $215 million in a series B funding round, bringing its total funding to $295 million. The company has been building a large data set of clinical immunological information to map out how the immune system functions. It uses machine learning to identify drug targets, predict patient responses, and develop cell therapies. Immunais data set, called the Annotated Multi-omic Immune Cell Atlas (AMICA), is claimed to be the largest in the world. The funding will be used to expand the workforce, enrich the data set, and strengthen the companys infrastructure. Immunai has collaborated with over 30 companies and academic institutions and has made two major acquisitions to accelerate the growth of its database.","partners":null,"customers":null,"investors":["Koch Disruptive Technologies","Talos VC","8VC","Alexandria Venture Investments","Piedmont","ICON"],"confidence":9,"key_topics":["Funding","Data analysis","Drug development","Partnerships","Data engineering"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":215000000,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"TQ4QjfzkjmELtRPWVkEeio3MWAEE77xgddtczbCfYJBMSyT5GEfGSm","news_summary":"Immunai announces a $215M Series B as its 'immune cell atlas' matures","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"07f33441-bd5f-475c-9d9f-8dc494b75af4","date":"Aug 1, 2021","link":"https://www.startupticker.ch/en/news/nebion-becomes-a-subsidiary-of-new-york-based-immunai#.YQfWapqKffo.twitter","source":"www.startupticker.ch","visible":1,"analysis":{"tags":"acquisition","company":"Immunai","layoffs":null,"summary":"Immunai has announced the acquisition of Swiss bioinformatics company Nebion to expand its discovery and drug development capabilities. Nebion will become a wholly-owned subsidiary operating under the same name. The acquisition will allow Immunai to incorporate Nebions curated public datasets to improve its machine learning models and find drug targets. Immunai has also brought on renowned executives, including Robert Langer, Jacques Banchereau, and Mark Jacobstein. Immunai has raised over $90M in capital to date.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Immunai","Nebion","acquisition","expansion","executives"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition"],"acquisition_amount":null,"structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cgJLJMulHEopch46gtLJqq4XnEiGpuJDvXVDHsLGmj3Ovy8yYtHSOa","news_summary":"Nebion becomes a subsidiary of New-York based Immunai","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"d67e4330-98b2-4837-a206-2ca8dc320346","date":"Jul 19, 2021","link":"https://www.israel21c.org/creating-a-google-maps-for-the-immune-system/","source":"www.israel21c.org","visible":1,"analysis":{"tags":"immune system","company":"Immunai","layoffs":null,"summary":"Immunai, a Tel Aviv-based company, is mapping the human immune system to understand how it fights diseases and develop new drugs. The company uses a granular map of the immune system to identify patterns and develop therapies. Immunai is working with CAR-T cells for its initial treatments and has acquired Dropprint Genomics to enhance its drug development capabilities. The company has raised $80 million in funding and has a multidisciplinary team of experts. Immunai aims to study immune-related diseases together to find connections and accelerate learning. The company believes that mapping the immune system is only the first step and plans to use the map to reprogram the immune system. Immunai has been recognized as one of the most promising companies and is focused on driving change through data and software.","partners":null,"customers":null,"investors":["TLV Partners","Viola Ventures","Dexcel Pharma","iAngels"],"confidence":8,"key_topics":["human immune system","mapping","drug development","CAR-T cells","artificial intelligence"],"date_of_event":"2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"c8VsY6vxqoMZJEAS5iYxhbpQNkRl3U24aw4hj82vkjhTvFJsqoqXNC","news_summary":"Creating a vital map of the human immune system","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"466d984a-090f-4812-ac83-ef65f7ad72f6","date":"Mar 25, 2021","link":"https://www.webwire.com/ViewPressRel.asp?aId=271957","source":"www.webwire.com","visible":1,"analysis":{"tags":"acquisition","company":"Immunai","layoffs":null,"summary":"Immunai, a biotech company, has announced its acquisition of Dropprint Genomics, a single-cell genomics software company. The acquisition will support Immunais work in single cell functional genomics and the development of new therapies. Immunai has also expanded its leadership team and scientific advisory board. The company has raised $80M in funding from various investors.","partners":null,"customers":null,"investors":["Viola Ventures","TLV Partners","Schusterman Family Investments","Duquesne Family Office","Catalio Capital Management","Dexcel Pharma"],"confidence":9,"key_topics":["acquisition","expansion","functional genomics","single-cell sequencing","immune system"],"date_of_event":"2021-03-25","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$80M","structured_issues":["Acquisition","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Acquisition  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"OtobE9N0nn5BJEUpo6TYsuNt7cDRLba5idiqSyXh6MXkwizmshHUAO","news_summary":"Immunai Acquires Dropprint Genomics and Strengthens Leadership Team with Experts in Immunology to Expand Target Discovery Capabilities","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ea55f4e1-2081-4dc2-b8f3-9ed862454831","date":"Feb 11, 2021","link":"https://techcrunch.com/2021/02/11/immunai-raises-60m-as-it-expands-from-improving-immune-therapies-to-discovering-new-ones-too/","source":"techcrunch.com","visible":1,"analysis":{"tags":"biotech, immunotherapy","company":"Immunai","layoffs":null,"summary":"Biotech startup Immunai has raised $60 million in Series A funding, bringing its total raised to over $80 million. The company has established the largest database in the world for single cell immunity characteristics and has used its machine learning-powered platform to enhance existing immunotherapies. With the new funding, Immunai plans to expand into the development of new therapies based on its data and ML. The company uses a multiomic approach to analyze different types of biological data. Immunai has partnerships with leading immunological research organizations and aims to create new drugs based on its understanding of the human immune profile.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["biotech","machine learning","immunotherapy","data analysis","new therapies"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$60 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"wmINpp6ddAQnLiK4vu1g3P9vElq0xporGyhClBvfSHOsdgzZycHCB7","news_summary":"Immunai raises $60M as it expands from improving immune therapies to discovering new ones, too","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9e12c99d-a67f-4cc3-8515-59fb7449f023","date":"Dec 16, 2020","link":"https://medcitynews.com/2020/12/immunai-joins-10x-genomics-program-to-boost-drug-development/","source":"medcitynews.com","visible":1,"analysis":{"tags":"BioPharma, Artificial Intelligence","company":"Immunai","layoffs":null,"summary":"Immunai, a startup specializing in artificial intelligence and single-cell biology, has partnered with 10x Genomics to provide drugmakers with a better view of how a patients immune system responds to therapy. The partnership allows Immunai to become one of the first certified service providers for 10x Genomics in North America. By combining their technologies, the two companies aim to improve the understanding of the immune system and identify new potential drug combinations. Immunai, which emerged from stealth mode with $20 million in seed funding, has customers including drug companies and academic research institutions. The companys technology offers a more detailed look at cells and allows for the analysis of single-cell behavior on a larger scale.","partners":["10x Genomics"],"customers":["Baylor College of Medicine","University of Pennsylvania","Memorial Sloan Kettering"],"investors":null,"confidence":9,"key_topics":["Immunai","10x Genomics","artificial intelligence","single-cell biology","drugmakers"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ByZWXCzkSsmqtkkpGYrZRpTV9IFkajU6EdIYl9arBsAVR4bcfoobxq","news_summary":"Immunai joins 10x Genomics program to boost drug development","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"64474e52-8c9b-46f1-9f68-c136bfa5332b","date":"Sep 23, 2020","link":"https://en.globes.co.il/en/article-the-startup-databasing-our-immune-system-1001343602","source":"en.globes.co.il","visible":1,"analysis":{"tags":"immune system, drug development","company":"Immunai","layoffs":null,"summary":"Immunai is building a database to profile the interactions between immune system cells in states of health and disease. The company aims to develop drugs based on immune system manipulation in a more efficient and customized way. It generates revenue by providing access to its database to pharmaceutical companies and is expected to announce a joint development agreement with a major pharmaceutical company. Immunais technology is based on an AI system and unique capabilities for profiling single-cell activity. The company has raised $20 million from Viola Ventures and TLV Partners and has 30 employees in Tel Aviv.","partners":null,"customers":null,"investors":"Viola Ventures, TLV Partners","confidence":9,"key_topics":["Immunai","database","immune system","drug development","artificial intelligence"],"date_of_event":"September 23, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$20 million","structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"orvAVc30DD2I81hbPzWwaLMLrDcnbxopasLr5kXIveco0CuVLuulnf","news_summary":"The startup databasing our immune system","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"be905563-605a-49c5-bf06-6b5a1277566b","date":"May 14, 2020","link":"https://en.globes.co.il/en/article-immune-system-mapping-co-immunai-raises-20m-1001328678","source":"en.globes.co.il","visible":1,"analysis":{"tags":"cancer treatments, machine learning, drug development","company":"Immunai","layoffs":null,"summary":"Immunai, an Israeli-US personalized therapeutics company, has raised $20 million in funding for the development of its system for adapting treatments and accelerating drug development. The company uses machine learning and genetic sequencing technology to build a broad immunological database, aiming to make the effect of cancer treatments targeting the immune system more predictable. The funding round was led by Viola Ventures and TLV Partners. Immunai employs over 30 people in Tel Aviv and New York and collaborates with leading hospitals and pharmaceutical companies.","partners":null,"customers":null,"investors":["Viola Ventures","TLV Partners"],"confidence":9,"key_topics":["machine learning","cancer treatments","immune system","data platform","drug development"],"date_of_event":"May 14, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$20 million","structured_issues":["Investment","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"IABNNI8VHtk02ilM90ArOnfDEZbdfVkW5KIFF2gsGfjek53QfHHm1K","news_summary":"Immune system mapping co Immunai raises $20m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":13,"techcommunityinvolvement":null,"mediagallery":[{"id":"1ff076ce-b0f7-42c5-a10b-68ec61375b8a","timestamp":"2021-10-31 10:13:58.000000","resources_type":2,"resources_title":"","resources_file_name":"zU6sgXHcjmI","alt":"","imageurl":"https://img.youtube.com/vi/zU6sgXHcjmI/0.jpg","url":"http://youtu.be/zU6sgXHcjmI"},{"id":"56ff2142-cb9c-4c84-a297-7babf9d71d89","timestamp":"2019-10-02 10:02:26.000000","resources_type":1,"resources_title":"Immunai1","resources_file_name":"$YL17eNaoX3YmIvZ19RqqgDgJ7ewP4p7iS8Lea1BYTP2ilcaqwcXo9m","alt":"Immunai1 logo","cleanBucketUrl":"https://storage.googleapis.com/clean-finder-353810","imageurl":"https://storage.googleapis.com/clean-finder-353810/$YL17eNaoX3YmIvZ19RqqgDgJ7ewP4p7iS8Lea1BYTP2ilcaqwcXo9m","url":"https://storage.googleapis.com/clean-finder-353810/$YL17eNaoX3YmIvZ19RqqgDgJ7ewP4p7iS8Lea1BYTP2ilcaqwcXo9m"}],"tags":["clinical-trials","immunotherapy","unicorn-2021","digital-healthcare","hospitals","immunology","data-analytics","actionable-insights","pharma-companies","cancer","autoimmune-diseases","artificial-intelligence","machine-learning","deep-learning","cells"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZwIIIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuDl6YLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety7cLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvpscQIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuBqK4IDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu81fgLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuBqK4IDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","9pkFKhAdtUefh1vjY2WtUim8QONRKr5M6Xn70xMj6wt3qVmuIRYGcq"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"R&D","products":["AMICA"],"geomarkets":[],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":14,"lastfunding":"$215M","totalrounds":3,"fundingstage":"B","totalfunding":"$295M","publicinvestors":14,"lastpublicfunding":215000000,"totalpublicrounds":3,"totalpublicfunding":295000000},"team":[{"name":"Noam  Solomon","email":"noam@immunai.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4LKeidMKDA","bounced":false,"claimed":0,"founder":1,"urlname":"noam-solomon","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgit2HkAsM","position":"Co-founder & CEO","last_name":"Solomon","claimtoken":"921f3ef81f9797f153de34ac8bb0789fe6d6d45799866bfe412a6cc3b26705dc","first_name":"Noam ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/noam-solomon-142393129/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2020-01-30 12:19:34.000000","initials":"NS","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Luis Voloch","email":"luis@immunai.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4J720b4LDA","bounced":true,"claimed":0,"founder":1,"urlname":"luis-voloch","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgytTWlgkM","position":"Co-founder & CTO","last_name":"Voloch","claimtoken":"b26aa7d031bd822c485b96a22a287a592322360190ec2a38a761155346613401","first_name":"Luis","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/volochluis/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2020-01-30 12:19:33.000000","initials":"LV","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Danny Wells","email":"danny@immunai.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4PKH-bUIDA","bounced":true,"claimed":0,"founder":0,"urlname":"danny-wells","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgirKPkwkM","position":"Chief Translational Medicine Officer","last_name":"Wells","claimtoken":"6a61aca22d6aba06a8ade7f976887f177de316631376d7402d29de7a2d278431","first_name":"Danny","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/danny-wells-bb03453a/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2020-01-30 12:19:32.000000","initials":"DW","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoPW8rMQKDA","fullname":"Lena Rogovina"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoPu-g88JDA","fullname":"Maor Perlov"},"biverifydate":"2020-05-18T00:00:00.000Z","crunchbaseid":"immunai","lastupdator":"Maor Perlov","lastupdator_email":"maorperlov@gmail.com","creator":"Yotam Maman","creator_email":"yotamm1988@gmail.com","createdate":"2019-10-02T00:00:00.000Z","biverification":"Maor Perlov","sectorverification":"Lena Rogovina","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJDI4ZiaCgw","date":"Oct 2021","amount":"$215M","source":"https://techcrunch.com/2021/10/27/immunai-announces-a-215m-series-b-as-its-immune-cell-atlas-matures/, Ziv Idan from Gefen Capital","eventtype":"FundingRoundEvent","investment":[{"name":"Koch Disruptive Technologies","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/koch-disruptive-technologies","logokey":"$JLmWojKisHbeyuUTVetokpcTPNUAfWmFYb2m8M3UEwuiQ8fYd6wFgy","tagline":null,"urlname":"/investor_page/koch-disruptive-technologies","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4LqO7r0IDA","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"pGWjgCExn5tDr626KdIusujt7A8GvVXuiJTTlUU2YIXwXGlktfYxow","fundingsubtype":"Corporate VC","investorislead":1,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$JLmWojKisHbeyuUTVetokpcTPNUAfWmFYb2m8M3UEwuiQ8fYd6wFgy","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""},{"name":"ICON","type":"NGO","amount":0,"hidden":false,"country":"United States","fullurl":"/company_page/icon-1","logokey":"$2ig8dXwUeNRxuo4EbYLQ1TOUkpySrhyNXCmxujLcyeJY4EI8O8Lld4","tagline":"Non-profit Organization that Bridges the Gap Between the Israeli Tech Ecosystem and Silicon Valley","urlname":"/company_page/icon-1","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODbuPnZCgw","fundingtype":"NGO","leadpartner":null,"investmentid":"0GilgGOnAocjlZcvSscRylGZHuiQ0jYQQOyKZamhU7uUMynSkgt8c0","fundingsubtype":"","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$2ig8dXwUeNRxuo4EbYLQ1TOUkpySrhyNXCmxujLcyeJY4EI8O8Lld4","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"8VC","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/8vc","logokey":"$4YQJvbLhzMHsangZqkyTFJdmn4XHcDuLPVpal5YfaqoT7o6y53hmNv","tagline":null,"urlname":"/investor_page/8vc","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4N3xmvMKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"6JEpQvbDk1Tqn7ibVUY8UFFK2CIAXeXdVpw2vujGIZVETPNJSGwyt0","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$4YQJvbLhzMHsangZqkyTFJdmn4XHcDuLPVpal5YfaqoT7o6y53hmNv","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Piedmont Venture Capital","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/piedmont-venture-capital","logokey":"$Xh9DdkZKWPpfnILmxbepMRgs7JkCecdjSq8e77Ewn5jWyCxOmWiJeK","tagline":"","urlname":"/investor_page/piedmont-venture-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJDIwcmICAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"CH9A84Y0bQePD0RiI0TR1mwwuvFr0CIsiV861YnotrtaS18XPHpGu4","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Xh9DdkZKWPpfnILmxbepMRgs7JkCecdjSq8e77Ewn5jWyCxOmWiJeK","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Alexandria Venture Investments","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/alexandria-venture-investments","logokey":"$iR8w9Wh89U0dhpiHwT7mCw7xlUohcSUKtHHbFxq3wMfPE7NTbQuzMs","tagline":"","urlname":"/investor_page/alexandria-venture-investments","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJDw1aGMCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"HISR7BFDZUp1BHtyDi2cRagIdOzFc1d8koVJClAoinIHhTAg1ERsqg","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$iR8w9Wh89U0dhpiHwT7mCw7xlUohcSUKtHHbFxq3wMfPE7NTbQuzMs","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Gefen Capital","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/gefen-capital","logokey":"$ZI7b9eFCiOhZeoUvNSwZbsNUdJPyzReYxhUPIAVYoEcsiksRwxoXNw","tagline":null,"urlname":"/investor_page/gefen-capital","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwIGUvYsKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"MdZIJr3Yo2WYLGkaJmPCCl3g29VZjtSf3dfWWHYYyqup3H7M0T3U37","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ZI7b9eFCiOhZeoUvNSwZbsNUdJPyzReYxhUPIAVYoEcsiksRwxoXNw","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "},{"name":"Talis Capital","type":"Investor","amount":0,"hidden":false,"country":"United Kingdom","fullurl":"/investor_page/talis-capital","logokey":"$CDZEUTEJsM7By4o6T6a13JZ7v3silx7mwMRJ0XZdXZoG3mRgQIwlFd","tagline":"","urlname":"/investor_page/talis-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEqNrLCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"qz3dtvm9NHmuvBsMizZFQgpzhll23ylvBYADmGYTnSRvtJwC6CcvID","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$CDZEUTEJsM7By4o6T6a13JZ7v3silx7mwMRJ0XZdXZoG3mRgQIwlFd","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":215000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJDw1ezUCww","date":"Aug 2021","amount":"Undisclosed","source":"https://www.startupticker.ch/en/news/nebion-becomes-a-subsidiary-of-new-york-based-immunai#.YQfWapqKffo.twitter","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Nebion","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJCwit7TCww","acquiredcompany_mna_type":"Company","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/nebion","acquiredcompany_mna_logokey":"$9wqR1DNVUHNoKIbr9LTWQ9Skl9JnniKL5LYSM6hggATEyiktlLh38t","acquiredcompany_mna_urlname":"/company_page/nebion","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$9wqR1DNVUHNoKIbr9LTWQ9Skl9JnniKL5LYSM6hggATEyiktlLh38t","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJCI9JL0Cgw","date":"Mar 2021","amount":"Undisclosed","source":"https://www.webwire.com/ViewPressRel.asp?aId=271957","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":" Dropprint Genomics","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJCorrjdCQw","acquiredcompany_mna_type":"Company","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/dropprint-genomics","acquiredcompany_mna_logokey":"$i8joi7zcUgkBPcU4sGQVpwKhdbZhDmUROnbyh4bldoPQSwqta6G4xE","acquiredcompany_mna_urlname":"/company_page/dropprint-genomics","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$i8joi7zcUgkBPcU4sGQVpwKhdbZhDmUROnbyh4bldoPQSwqta6G4xE","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJCIparDCAw","date":"Feb 2021","amount":"$60M","source":"https://techcrunch.com/2021/02/11/immunai-raises-60m-as-it-expands-from-improving-immune-therapies-to-discovering-new-ones-too/, Ziv Idan from Gefen Capital","eventtype":"FundingRoundEvent","investment":[{"name":"Duquesne Family Office","type":"Other","amount":0,"hidden":false,"country":"United States","fullurl":"/company_page/duquesne-family-office","logokey":null,"tagline":"Family Office","urlname":"/company_page/duquesne-family-office","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCnnpWYCQw","fundingtype":"Other","leadpartner":null,"investmentid":"Gw1EF3yywn8zGElwffScTLfO2qhwepeDe1dC36RwOpaJILFeDIanjD","fundingsubtype":"","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/startups-icon.svg","leadcaption":"","followupcaption":""},{"name":"TLV Partners","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/tlv-partners","logokey":"$UbLE3HzYOydlfg8GLAPVzOIdGt3ekGRYqA28v5YgZvbttzYx3R2kVa.png","tagline":null,"urlname":"/investor_page/tlv-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOmdlpcJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"HFG2ocJE4zdgy9Qxgr5j7xfav7glTSyslDVOeK2GklR72jC3G7VGC2","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$UbLE3HzYOydlfg8GLAPVzOIdGt3ekGRYqA28v5YgZvbttzYx3R2kVa.png","leadcaption":"","followupcaption":"Follow on "},{"name":"Schusterman Family Investments ","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/schusterman-family-investments-1","logokey":"$kQaCOXhojZerLybYEBysGKHJWPJR8eiG0pzz0wrCWJ4CZJc9Mxf3uz","tagline":"investing across multiple asset classes in both the private and public markets.","urlname":"/investor_page/schusterman-family-investments-1","isisraeli":0,"investorid":"n4OiuhNVXsW0UBP4bLcW5MHod2KRODEnwQoAJWL6VmQYksV8rZdgkS","fundingtype":"Family Office","leadpartner":null,"investmentid":"IGM8Kh6EQKN4LwkM2vHCUgV2XW8v87S5dlMjefc0nUtSLGBzz9mPHn","fundingsubtype":"Family Office","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$kQaCOXhojZerLybYEBysGKHJWPJR8eiG0pzz0wrCWJ4CZJc9Mxf3uz","leadcaption":"","followupcaption":""},{"name":"Catalio Capital Management","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/catalio-capital-management","logokey":"$pzTxwj9KEiYpTXluAEqG5dkWgJy9EeXsNbKatE2HXv83NUETT1XkxZ","tagline":"","urlname":"/investor_page/catalio-capital-management","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJDwgbnWCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"OxMkdcHiC0uAOsEX2ej4gjOKYOv2r1QvYYRcfIqHX7YeDrOx8WrSug","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$pzTxwj9KEiYpTXluAEqG5dkWgJy9EeXsNbKatE2HXv83NUETT1XkxZ","leadcaption":"","followupcaption":""},{"name":"Meron Capital","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/meron-capital","logokey":"$3w8nw5WhsnXvv2QFMoiLuUzeJSnoClCejaUvi8wRrmc00wSR5YTUB0","tagline":null,"urlname":"/investor_page/meron-capital","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwNWayJkLDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"V8ySHRw4Ru54Mn9DiamSPpbAmtbj2yzFacLwFvNzO6HauUxwUaKI1m","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$3w8nw5WhsnXvv2QFMoiLuUzeJSnoClCejaUvi8wRrmc00wSR5YTUB0","leadcaption":"","followupcaption":""},{"name":"Viola Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/viola-ventures","logokey":"$kZjPyVJv2EUbggBPSpYvV9IKWjpBmmjkvUtmPNskVuIx5mjDAw616L.png","tagline":null,"urlname":"/investor_page/viola-ventures","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP7Vmc4KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"nCUSbIAbRYJCWQpuT29dXpeQvV2ohfZnzG8FDSrvcrCndpDkftThJS","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$kZjPyVJv2EUbggBPSpYvV9IKWjpBmmjkvUtmPNskVuIx5mjDAw616L.png","leadcaption":"","followupcaption":"Follow on "},{"name":"Gefen Capital","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/gefen-capital","logokey":"$ZI7b9eFCiOhZeoUvNSwZbsNUdJPyzReYxhUPIAVYoEcsiksRwxoXNw","tagline":null,"urlname":"/investor_page/gefen-capital","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwIGUvYsKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"vgfhnQNQ730PrUNfYLCC96gbrAMxxA4yXx49cIbTx0tFnIJAYmq6Lu","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ZI7b9eFCiOhZeoUvNSwZbsNUdJPyzReYxhUPIAVYoEcsiksRwxoXNw","leadcaption":"","followupcaption":"Follow on "},{"name":"Dexcel Pharma","type":"Startup","amount":0,"hidden":false,"country":"Israel","fullurl":"/company_page/dexcel","logokey":"$NNIYTGxlzKUuDbfe9wlG0gp96U8zAzcGAUjZC1UU0PL5ecQVbrMMau","tagline":"New Formulations of Known Molecules and Complex Generic Drugs","urlname":"/company_page/dexcel","isisraeli":null,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL7sjooJDA","fundingtype":"Startup","leadpartner":null,"investmentid":"wq67QlizAhkVWuX8Hgfgzr2jx6P00r4Hd67HSqL4g3w4bPAxeJYd7J","fundingsubtype":"","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$NNIYTGxlzKUuDbfe9wlG0gp96U8zAzcGAUjZC1UU0PL5ecQVbrMMau","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":60000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODS0du-Cgw","date":"May 2020","amount":"$20M","source":"https://en.globes.co.il/en/article-immune-system-mapping-co-immunai-raises-20m-1001328678ת Ziv Idan from Gefen Capital","eventtype":"FundingRoundEvent","investment":[{"name":"TLV Partners","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/tlv-partners","logokey":"$UbLE3HzYOydlfg8GLAPVzOIdGt3ekGRYqA28v5YgZvbttzYx3R2kVa.png","tagline":null,"urlname":"/investor_page/tlv-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOmdlpcJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"h3qrQ9eQ9dZuCXfNIQw2UMOOuAXtYAl97D18mY8JLXsEwjf4VVOB5A","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$UbLE3HzYOydlfg8GLAPVzOIdGt3ekGRYqA28v5YgZvbttzYx3R2kVa.png","leadcaption":"Lead ","followupcaption":""},{"name":"Gefen Capital","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/gefen-capital","logokey":"$ZI7b9eFCiOhZeoUvNSwZbsNUdJPyzReYxhUPIAVYoEcsiksRwxoXNw","tagline":null,"urlname":"/investor_page/gefen-capital","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwIGUvYsKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"AP5pI7NWDp3ykhNIeJFzZWE90VO8C6twnriczaoLPFmz9ftxJeaULf","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ZI7b9eFCiOhZeoUvNSwZbsNUdJPyzReYxhUPIAVYoEcsiksRwxoXNw","leadcaption":"","followupcaption":""},{"name":"Viola Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/viola-ventures","logokey":"$kZjPyVJv2EUbggBPSpYvV9IKWjpBmmjkvUtmPNskVuIx5mjDAw616L.png","tagline":null,"urlname":"/investor_page/viola-ventures","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP7Vmc4KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"F4j3zhoH1MZnAAKVx8AtjXwqnA2k1zSSwo4WEk9tKxh28ktglKtmeZ","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$kZjPyVJv2EUbggBPSpYvV9IKWjpBmmjkvUtmPNskVuIx5mjDAw616L.png","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":20000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"AUkfdEQOPKqzEcoT0wAjW7gjETjufP3mO449ihk7888W9bvAQoFgXw","hub":"Arc Innovation Center","date":"","batch":"","amount":"Undisclosed","hub_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Nzf9a0IDA","source":"","enddate":"","hub_type":"Corporate Accelerator","eventtype":"GraduationEvent","hub_hidden":false,"investment":[],"hub_fullurl":"/program_page/arc-innovation-center","hub_logokey":"$h4kVs9Y8FIw1PlL9peLoiBUHlwkeM0hVe5lCktvnAuF1BF3VW20V0c","hub_urlname":"/program_page/arc-innovation-center","eventvisibility":null,"amountvisibility":null,"fundingvisibility":null,"style":"","hiddenCompanyTooltip":"","hub_logourl":"https://storage.googleapis.com/clean-finder-353810/$h4kVs9Y8FIw1PlL9peLoiBUHlwkeM0hVe5lCktvnAuF1BF3VW20V0c","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"HFNga3rMI8LeJEjzsRo9SObvWqQYPJqaxvagGlfOcLBlvlX41WkRuG","hub":"SV101 By ICON","date":"","batch":"","amount":"Undisclosed","hub_id":"hLodxDzPSMF9NSRt0ccogQujl1qyQN8n1BNq1T6Jpd7QMwQcyP9WYE","source":"","enddate":"","hub_type":"Entrepreneurship Program","eventtype":"GraduationEvent","hub_hidden":false,"investment":[],"hub_fullurl":"/program_page/sv101-by-icon","hub_logokey":"$ej9VeKt6pyzac8cO3XZVyaLWOZa72JalipzpgDxDPEt5mcfL7rtlaf.jpg","hub_urlname":"/program_page/sv101-by-icon","eventvisibility":null,"amountvisibility":null,"fundingvisibility":null,"style":"","hiddenCompanyTooltip":"","hub_logourl":"https://storage.googleapis.com/clean-finder-353810/$ej9VeKt6pyzac8cO3XZVyaLWOZa72JalipzpgDxDPEt5mcfL7rtlaf.jpg","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"1/2019","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Immunai","logourl":"https://storage.googleapis.com/clean-finder-353810/$GH8p88MaCJb7c2NVf1vof017FyaDsnVb831iA8QvgkNVu2yfTkaAuK","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$GH8p88MaCJb7c2NVf1vof017FyaDsnVb831iA8QvgkNVu2yfTkaAuK","seoabout":"Immunai is developing a proprietary data set of multi-omic, immune-centric peripheral tissue analyses. The company's advanced analytics and data-visualizat...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":3,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Business Software","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZwIIIDA","classificationName":"sectorclassification"},{"depth":2,"name":"IT, R&D & Data Solutions","queryString":"sectorclassification=9pkFKhAdtUefh1vjY2WtUim8QONRKr5M6Xn70xMj6wt3qVmuIRYGcq","classificationName":"sectorclassification"},{"depth":3,"name":"Data Analysis & Decision Support","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuBqK4IDA","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Digital Healthcare","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Decision Support","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety7cLDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Artificial Intelligence","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","classificationName":"coretechnology"},{"depth":2,"name":"Deep Learning","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuDl6YLDA","classificationName":"coretechnology"},{"depth":2,"name":"Machine Learning","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu81fgLDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Laboratories","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvpscQIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Business Software#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZwIIIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA>Deep Learning#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuDl6YLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA>Medical Decision Support#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety7cLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Laboratories#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvpscQIDA","SectorClassificationModel>Business Software#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZwIIIDA>IT, R&D & Data Solutions#9pkFKhAdtUefh1vjY2WtUim8QONRKr5M6Xn70xMj6wt3qVmuIRYGcq>Data Analysis & Decision Support#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuBqK4IDA","TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA>Machine Learning#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu81fgLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","SectorClassificationModel>Business Software#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZwIIIDA>IT, R&D & Data Solutions#9pkFKhAdtUefh1vjY2WtUim8QONRKr5M6Xn70xMj6wt3qVmuIRYGcq>Data Analysis & Decision Support#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuBqK4IDA","TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Business Software#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZwIIIDA>IT, R&D & Data Solutions#9pkFKhAdtUefh1vjY2WtUim8QONRKr5M6Xn70xMj6wt3qVmuIRYGcq"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Business Software#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZwIIIDA|2:>SectorClassificationModel>Business Software#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZwIIIDA/IT, R&D & Data Solutions#9pkFKhAdtUefh1vjY2WtUim8QONRKr5M6Xn70xMj6wt3qVmuIRYGcq|3:>SectorClassificationModel>Business Software#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZwIIIDA>IT, R&D & Data Solutions#9pkFKhAdtUefh1vjY2WtUim8QONRKr5M6Xn70xMj6wt3qVmuIRYGcq/Data Analysis & Decision Support#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuBqK4IDA|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA/Medical Decision Support#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety7cLDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA|2:>TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA/Deep Learning#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuDl6YLDA|2:>TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA/Machine Learning#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu81fgLDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Laboratories#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvpscQIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|","classificationTrees":{"sector":[{"title":"Business Software","key":"0-0","path":"SectorClassificationModel>Business Software","children":[{"title":"IT, R&D & Data Solutions","key":"0-0-0","path":"SectorClassificationModel>Business Software>IT, R&D & Data Solutions","children":[{"title":"Data Analysis & Decision Support","key":"0-0-0-0","path":"SectorClassificationModel>Business Software>IT, R&D & Data Solutions>Data Analysis & Decision Support"}]}]},{"title":"Health Tech & Life Sciences","key":"0-1","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Digital Healthcare","key":"0-1-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Digital Healthcare","children":[{"title":"Medical Decision Support","key":"0-1-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Digital Healthcare>Medical Decision Support"}]},{"title":"Pharma & Medical Biotechnology","key":"0-1-1","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-1-1-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Laboratories","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Laboratories"},{"title":"Providers","key":"0-0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Providers"}]},{"title":"Life Sciences","key":"0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-1-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Artificial Intelligence","key":"0-0","path":"TechnologyClassificationModel>Artificial Intelligence","children":[{"title":"Deep Learning","key":"0-0-0","path":"TechnologyClassificationModel>Artificial Intelligence>Deep Learning"},{"title":"Machine Learning","key":"0-0-1","path":"TechnologyClassificationModel>Artificial Intelligence>Machine Learning"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Business Software","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZwIIIDA","classificationName":"sectorclassification"},{"depth":2,"name":"IT, R&D & Data Solutions","queryString":"sectorclassification=9pkFKhAdtUefh1vjY2WtUim8QONRKr5M6Xn70xMj6wt3qVmuIRYGcq","classificationName":"sectorclassification"},{"depth":3,"name":"Data Analysis & Decision Support","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuBqK4IDA","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Digital Healthcare","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Decision Support","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety7cLDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Artificial Intelligence","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","classificationName":"coretechnology"},{"depth":2,"name":"Deep Learning","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuDl6YLDA","classificationName":"coretechnology"},{"depth":2,"name":"Machine Learning","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu81fgLDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Laboratories","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvpscQIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Business Software","IT, R&D & Data Solutions","Data Analysis & Decision Support","Health Tech & Life Sciences","Digital Healthcare","Medical Decision Support","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Artificial Intelligence","Deep Learning","Machine Learning"],"targetCustomer":["Healthcare & Life Sciences","Healthcare","Laboratories","Providers","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJDI4ZiaCgw","date":"Oct 2021","amount":"$215M","source":"https://techcrunch.com/2021/10/27/immunai-announces-a-215m-series-b-as-its-immune-cell-atlas-matures/, Ziv Idan from Gefen Capital","eventtype":"FundingRoundEvent","investment":[{"name":"Koch Disruptive Technologies","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/koch-disruptive-technologies","logokey":"$JLmWojKisHbeyuUTVetokpcTPNUAfWmFYb2m8M3UEwuiQ8fYd6wFgy","tagline":null,"urlname":"/investor_page/koch-disruptive-technologies","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4LqO7r0IDA","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"pGWjgCExn5tDr626KdIusujt7A8GvVXuiJTTlUU2YIXwXGlktfYxow","fundingsubtype":"Corporate VC","investorislead":1,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$JLmWojKisHbeyuUTVetokpcTPNUAfWmFYb2m8M3UEwuiQ8fYd6wFgy","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""},{"name":"ICON","type":"NGO","amount":0,"hidden":false,"country":"United States","fullurl":"/company_page/icon-1","logokey":"$2ig8dXwUeNRxuo4EbYLQ1TOUkpySrhyNXCmxujLcyeJY4EI8O8Lld4","tagline":"Non-profit Organization that Bridges the Gap Between the Israeli Tech Ecosystem and Silicon Valley","urlname":"/company_page/icon-1","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODbuPnZCgw","fundingtype":"NGO","leadpartner":null,"investmentid":"0GilgGOnAocjlZcvSscRylGZHuiQ0jYQQOyKZamhU7uUMynSkgt8c0","fundingsubtype":"","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$2ig8dXwUeNRxuo4EbYLQ1TOUkpySrhyNXCmxujLcyeJY4EI8O8Lld4","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"8VC","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/8vc","logokey":"$4YQJvbLhzMHsangZqkyTFJdmn4XHcDuLPVpal5YfaqoT7o6y53hmNv","tagline":null,"urlname":"/investor_page/8vc","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4N3xmvMKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"6JEpQvbDk1Tqn7ibVUY8UFFK2CIAXeXdVpw2vujGIZVETPNJSGwyt0","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$4YQJvbLhzMHsangZqkyTFJdmn4XHcDuLPVpal5YfaqoT7o6y53hmNv","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Piedmont Venture Capital","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/piedmont-venture-capital","logokey":"$Xh9DdkZKWPpfnILmxbepMRgs7JkCecdjSq8e77Ewn5jWyCxOmWiJeK","tagline":"","urlname":"/investor_page/piedmont-venture-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJDIwcmICAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"CH9A84Y0bQePD0RiI0TR1mwwuvFr0CIsiV861YnotrtaS18XPHpGu4","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Xh9DdkZKWPpfnILmxbepMRgs7JkCecdjSq8e77Ewn5jWyCxOmWiJeK","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Alexandria Venture Investments","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/alexandria-venture-investments","logokey":"$iR8w9Wh89U0dhpiHwT7mCw7xlUohcSUKtHHbFxq3wMfPE7NTbQuzMs","tagline":"","urlname":"/investor_page/alexandria-venture-investments","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJDw1aGMCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"HISR7BFDZUp1BHtyDi2cRagIdOzFc1d8koVJClAoinIHhTAg1ERsqg","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$iR8w9Wh89U0dhpiHwT7mCw7xlUohcSUKtHHbFxq3wMfPE7NTbQuzMs","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Gefen Capital","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/gefen-capital","logokey":"$ZI7b9eFCiOhZeoUvNSwZbsNUdJPyzReYxhUPIAVYoEcsiksRwxoXNw","tagline":null,"urlname":"/investor_page/gefen-capital","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwIGUvYsKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"MdZIJr3Yo2WYLGkaJmPCCl3g29VZjtSf3dfWWHYYyqup3H7M0T3U37","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ZI7b9eFCiOhZeoUvNSwZbsNUdJPyzReYxhUPIAVYoEcsiksRwxoXNw","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "},{"name":"Talis Capital","type":"Investor","amount":0,"hidden":false,"country":"United Kingdom","fullurl":"/investor_page/talis-capital","logokey":"$CDZEUTEJsM7By4o6T6a13JZ7v3silx7mwMRJ0XZdXZoG3mRgQIwlFd","tagline":"","urlname":"/investor_page/talis-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEqNrLCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"qz3dtvm9NHmuvBsMizZFQgpzhll23ylvBYADmGYTnSRvtJwC6CcvID","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$CDZEUTEJsM7By4o6T6a13JZ7v3silx7mwMRJ0XZdXZoG3mRgQIwlFd","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":215000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJCIparDCAw","date":"Feb 2021","amount":"$60M","source":"https://techcrunch.com/2021/02/11/immunai-raises-60m-as-it-expands-from-improving-immune-therapies-to-discovering-new-ones-too/, Ziv Idan from Gefen Capital","eventtype":"FundingRoundEvent","investment":[{"name":"Duquesne Family Office","type":"Other","amount":0,"hidden":false,"country":"United States","fullurl":"/company_page/duquesne-family-office","logokey":null,"tagline":"Family Office","urlname":"/company_page/duquesne-family-office","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCnnpWYCQw","fundingtype":"Other","leadpartner":null,"investmentid":"Gw1EF3yywn8zGElwffScTLfO2qhwepeDe1dC36RwOpaJILFeDIanjD","fundingsubtype":"","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/startups-icon.svg","leadcaption":"","followupcaption":""},{"name":"TLV Partners","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/tlv-partners","logokey":"$UbLE3HzYOydlfg8GLAPVzOIdGt3ekGRYqA28v5YgZvbttzYx3R2kVa.png","tagline":null,"urlname":"/investor_page/tlv-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOmdlpcJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"HFG2ocJE4zdgy9Qxgr5j7xfav7glTSyslDVOeK2GklR72jC3G7VGC2","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$UbLE3HzYOydlfg8GLAPVzOIdGt3ekGRYqA28v5YgZvbttzYx3R2kVa.png","leadcaption":"","followupcaption":"Follow on "},{"name":"Schusterman Family Investments ","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/schusterman-family-investments-1","logokey":"$kQaCOXhojZerLybYEBysGKHJWPJR8eiG0pzz0wrCWJ4CZJc9Mxf3uz","tagline":"investing across multiple asset classes in both the private and public markets.","urlname":"/investor_page/schusterman-family-investments-1","isisraeli":0,"investorid":"n4OiuhNVXsW0UBP4bLcW5MHod2KRODEnwQoAJWL6VmQYksV8rZdgkS","fundingtype":"Family Office","leadpartner":null,"investmentid":"IGM8Kh6EQKN4LwkM2vHCUgV2XW8v87S5dlMjefc0nUtSLGBzz9mPHn","fundingsubtype":"Family Office","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$kQaCOXhojZerLybYEBysGKHJWPJR8eiG0pzz0wrCWJ4CZJc9Mxf3uz","leadcaption":"","followupcaption":""},{"name":"Catalio Capital Management","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/catalio-capital-management","logokey":"$pzTxwj9KEiYpTXluAEqG5dkWgJy9EeXsNbKatE2HXv83NUETT1XkxZ","tagline":"","urlname":"/investor_page/catalio-capital-management","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJDwgbnWCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"OxMkdcHiC0uAOsEX2ej4gjOKYOv2r1QvYYRcfIqHX7YeDrOx8WrSug","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$pzTxwj9KEiYpTXluAEqG5dkWgJy9EeXsNbKatE2HXv83NUETT1XkxZ","leadcaption":"","followupcaption":""},{"name":"Meron Capital","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/meron-capital","logokey":"$3w8nw5WhsnXvv2QFMoiLuUzeJSnoClCejaUvi8wRrmc00wSR5YTUB0","tagline":null,"urlname":"/investor_page/meron-capital","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwNWayJkLDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"V8ySHRw4Ru54Mn9DiamSPpbAmtbj2yzFacLwFvNzO6HauUxwUaKI1m","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$3w8nw5WhsnXvv2QFMoiLuUzeJSnoClCejaUvi8wRrmc00wSR5YTUB0","leadcaption":"","followupcaption":""},{"name":"Viola Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/viola-ventures","logokey":"$kZjPyVJv2EUbggBPSpYvV9IKWjpBmmjkvUtmPNskVuIx5mjDAw616L.png","tagline":null,"urlname":"/investor_page/viola-ventures","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP7Vmc4KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"nCUSbIAbRYJCWQpuT29dXpeQvV2ohfZnzG8FDSrvcrCndpDkftThJS","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$kZjPyVJv2EUbggBPSpYvV9IKWjpBmmjkvUtmPNskVuIx5mjDAw616L.png","leadcaption":"","followupcaption":"Follow on "},{"name":"Gefen Capital","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/gefen-capital","logokey":"$ZI7b9eFCiOhZeoUvNSwZbsNUdJPyzReYxhUPIAVYoEcsiksRwxoXNw","tagline":null,"urlname":"/investor_page/gefen-capital","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwIGUvYsKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"vgfhnQNQ730PrUNfYLCC96gbrAMxxA4yXx49cIbTx0tFnIJAYmq6Lu","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ZI7b9eFCiOhZeoUvNSwZbsNUdJPyzReYxhUPIAVYoEcsiksRwxoXNw","leadcaption":"","followupcaption":"Follow on "},{"name":"Dexcel Pharma","type":"Startup","amount":0,"hidden":false,"country":"Israel","fullurl":"/company_page/dexcel","logokey":"$NNIYTGxlzKUuDbfe9wlG0gp96U8zAzcGAUjZC1UU0PL5ecQVbrMMau","tagline":"New Formulations of Known Molecules and Complex Generic Drugs","urlname":"/company_page/dexcel","isisraeli":null,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL7sjooJDA","fundingtype":"Startup","leadpartner":null,"investmentid":"wq67QlizAhkVWuX8Hgfgzr2jx6P00r4Hd67HSqL4g3w4bPAxeJYd7J","fundingsubtype":"","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$NNIYTGxlzKUuDbfe9wlG0gp96U8zAzcGAUjZC1UU0PL5ecQVbrMMau","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":60000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODS0du-Cgw","date":"May 2020","amount":"$20M","source":"https://en.globes.co.il/en/article-immune-system-mapping-co-immunai-raises-20m-1001328678ת Ziv Idan from Gefen Capital","eventtype":"FundingRoundEvent","investment":[{"name":"TLV Partners","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/tlv-partners","logokey":"$UbLE3HzYOydlfg8GLAPVzOIdGt3ekGRYqA28v5YgZvbttzYx3R2kVa.png","tagline":null,"urlname":"/investor_page/tlv-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOmdlpcJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"h3qrQ9eQ9dZuCXfNIQw2UMOOuAXtYAl97D18mY8JLXsEwjf4VVOB5A","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$UbLE3HzYOydlfg8GLAPVzOIdGt3ekGRYqA28v5YgZvbttzYx3R2kVa.png","leadcaption":"Lead ","followupcaption":""},{"name":"Gefen Capital","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/gefen-capital","logokey":"$ZI7b9eFCiOhZeoUvNSwZbsNUdJPyzReYxhUPIAVYoEcsiksRwxoXNw","tagline":null,"urlname":"/investor_page/gefen-capital","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwIGUvYsKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"AP5pI7NWDp3ykhNIeJFzZWE90VO8C6twnriczaoLPFmz9ftxJeaULf","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ZI7b9eFCiOhZeoUvNSwZbsNUdJPyzReYxhUPIAVYoEcsiksRwxoXNw","leadcaption":"","followupcaption":""},{"name":"Viola Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/viola-ventures","logokey":"$kZjPyVJv2EUbggBPSpYvV9IKWjpBmmjkvUtmPNskVuIx5mjDAw616L.png","tagline":null,"urlname":"/investor_page/viola-ventures","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP7Vmc4KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"F4j3zhoH1MZnAAKVx8AtjXwqnA2k1zSSwo4WEk9tKxh28ktglKtmeZ","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$kZjPyVJv2EUbggBPSpYvV9IKWjpBmmjkvUtmPNskVuIx5mjDAw616L.png","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":20000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJDw1ezUCww","date":"Aug 2021","amount":"Undisclosed","source":"https://www.startupticker.ch/en/news/nebion-becomes-a-subsidiary-of-new-york-based-immunai#.YQfWapqKffo.twitter","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Nebion","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJCwit7TCww","acquiredcompany_mna_type":"Company","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/nebion","acquiredcompany_mna_logokey":"$9wqR1DNVUHNoKIbr9LTWQ9Skl9JnniKL5LYSM6hggATEyiktlLh38t","acquiredcompany_mna_urlname":"/company_page/nebion","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$9wqR1DNVUHNoKIbr9LTWQ9Skl9JnniKL5LYSM6hggATEyiktlLh38t","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJCI9JL0Cgw","date":"Mar 2021","amount":"Undisclosed","source":"https://www.webwire.com/ViewPressRel.asp?aId=271957","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":" Dropprint Genomics","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJCorrjdCQw","acquiredcompany_mna_type":"Company","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/dropprint-genomics","acquiredcompany_mna_logokey":"$i8joi7zcUgkBPcU4sGQVpwKhdbZhDmUROnbyh4bldoPQSwqta6G4xE","acquiredcompany_mna_urlname":"/company_page/dropprint-genomics","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$i8joi7zcUgkBPcU4sGQVpwKhdbZhDmUROnbyh4bldoPQSwqta6G4xE","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"others":[]}}